search
Back to results

Effects of Ranibizumab in Primary Pterygium Surgery

Primary Purpose

Patients With Primary Nasal Pterygium

Status
Completed
Phase
Phase 1
Locations
Malaysia
Study Type
Interventional
Intervention
intralesional ranibizumab
Sponsored by
Universiti Sains Malaysia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patients With Primary Nasal Pterygium

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • primary nasal grade 2 to 3 pterygium based on the clinical stages outlined by Johnston et al (2004)
  • who consented for pterygium excision and conjunctival autograft surgery

Exclusion Criteria:

  • cornea pathology such as scarring, history of herpetic keratitis, eyelid abnormalities, previous ocular surgery, ocular trauma, and ocular or systemic inflammatory disease
  • Pregnant women and lactating mothers

Sites / Locations

  • Hospital Universiti Sains Malaysia

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control group

Intervention group

Arm Description

No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery

The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery

Outcomes

Primary Outcome Measures

Microvascular Density (MVD) using anti-CD34 antibody staining, classified based on the Weidner scoring system.
MVD is a reflection of angiogenesis (Norrby, 1998). The effects of anti-VEGF on MVD of the excised tissue were assessed using anti-CD34 antibody (50 µg at 1 mg/ml at dilution of 1:50-1:100, QBEnd/10, Mouse anti-Human, Dako, North America).

Secondary Outcome Measures

Oxidative Stress using eight-hydroxyguanosine (8-OHdG) staining, based on the percentage of positively stained cells viewed under 400x high-power field magnification.
8-OHdG is an oxidative stress biomarker which has been observed to have a significant association with primary pterygium Ismaeel et al. (2010).

Full Information

First Posted
April 26, 2021
Last Updated
May 6, 2021
Sponsor
Universiti Sains Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT04878835
Brief Title
Effects of Ranibizumab in Primary Pterygium Surgery
Official Title
Effects of Ranibizumab on Microvasculature, Oxidative Stress and Recurrence in Primary Pterygium Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
April 1, 2020 (Actual)
Study Completion Date
April 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Sains Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pterygium is a common ocular surface disease in Malaysia. Without treatment, it can lead to severe visual impairment. Recurrence is the commonest complication and novel treatment approaches are crucial to prevent vision loss. The biological processes underlying the formation of pterygium are complex, but central to its pathogenesis is the angiogenic cytokine vascular endothelial growth factor (VEGF). VEGF is upregulated under conditions of increased oxidative stress, which plays an integral role in pterygium development (Cardenas-Cantu et al., 2016, Karaman, 2018, Norrby, 1998, Rossino et al., 2020, Shibunya, 2011).Various biomarkers on pterygium have been identified and are useful to determine the effectiveness of new modality treatment for pterygium. These markers can be identified via histopathological stain such as Masson Trichrome to observe changes of collagen fibres. Other identifiable markers include the use of special immunohistochemical stain such as anti CD34 antibody for microvascular density and anti-8-OHdG antibody for oxidative changes in the pterygium tissue. By analyzing the changes with or without Ranibizumab injection in addition to observation of clinical recurrence rate of pterygium, we are able to conclude the effectiveness of anti-VEGF on pterygium recurrence. The aim of the study was to evaluate the association between collagen fibres changes, microvascular density changes and inflammation resultant from oxidative stress with the clinical recurrence of pterygium following intralesional Ranibizumab injection in comparison to control group.
Detailed Description
This is a prospective interventional study conducted from May 2018 to April 2020. Patients with primary pterygium who attended eye clinic Hospital Universiti Sains Malaysia (HUSM) Kubang Kerian, Kelantan and fulfilled the inclusion and exclusion criteria were recruited as participants of this study. Convenient sampling method was applied for participants' recruitment where all patients will be given thorough explanation in regards to the study and subsequently divided into interventional and control group. Intervention group participants were given intralesional Ranibizumab (0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery. Both groups of participants undergo pterygium excision with autologous conjunctival graft surgery thereafter. Excised pterygium tissues were sent to the laboratory for slide preparation and staining with specific reagents including Masson Trichrome for collagen fibers, anti CD34 antibody for microvascular density and anti-8 OHdG antibody for oxidative stress changes. Slides were then analysed by the pathologist and statistical analysis of the results were carried out with the Statistical Package for the Social Sciences (SPSS) Version 26.0. All participants had intralesional Ranibizumab injection and pterygium excision with autologous conjunctival graft surgery in May 2018. They were scheduled for follow-up visits for the next 24 months to observe for complications of intralesional Ranibizumab injection, pterygium excision and conjunctival autograft surgery and any signs of recurrence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patients With Primary Nasal Pterygium

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
Intervention Type
Biological
Intervention Name(s)
intralesional ranibizumab
Intervention Description
Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
Primary Outcome Measure Information:
Title
Microvascular Density (MVD) using anti-CD34 antibody staining, classified based on the Weidner scoring system.
Description
MVD is a reflection of angiogenesis (Norrby, 1998). The effects of anti-VEGF on MVD of the excised tissue were assessed using anti-CD34 antibody (50 µg at 1 mg/ml at dilution of 1:50-1:100, QBEnd/10, Mouse anti-Human, Dako, North America).
Time Frame
After pterygium excision surgery, tissues were sent to the histopathological laboratory where microvascular density was assessed within two weeks
Secondary Outcome Measure Information:
Title
Oxidative Stress using eight-hydroxyguanosine (8-OHdG) staining, based on the percentage of positively stained cells viewed under 400x high-power field magnification.
Description
8-OHdG is an oxidative stress biomarker which has been observed to have a significant association with primary pterygium Ismaeel et al. (2010).
Time Frame
After pterygium excision surgery, tissues were sent to the histopathological laboratory where assessment for oxidative stress via 8-OHdG staining was performed within two weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: primary nasal grade 2 to 3 pterygium based on the clinical stages outlined by Johnston et al (2004) who consented for pterygium excision and conjunctival autograft surgery Exclusion Criteria: cornea pathology such as scarring, history of herpetic keratitis, eyelid abnormalities, previous ocular surgery, ocular trauma, and ocular or systemic inflammatory disease Pregnant women and lactating mothers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin Yi Yap, MMed
Organizational Affiliation
Universiti Sains Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universiti Sains Malaysia
City
Kota Bharu
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22553564
Citation
Ismaeel OM, Jaafar H, Ibrahim M. Detection of 8-hydroxydeoxyguanosine enzyme in recurrent pterygium raising a question on its role on recurrence. Int J Ophthalmol. 2010;3(3):245-8. doi: 10.3980/j.issn.2222-3959.2010.03.15. Epub 2010 Sep 18.
Results Reference
background
Citation
Johnston SC, Williams PB, Sheppard JDJr. A Comprehensive System for Pterygium Classification. Invest Ophthalmol Vis Sci. 2004; 45(13): 2940.
Results Reference
background
PubMed Identifier
9473408
Citation
Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res. 1998 Jan;55(1):43-53. doi: 10.1006/mvre.1997.2054.
Results Reference
background
PubMed Identifier
22866201
Citation
Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011 Dec;2(12):1097-105. doi: 10.1177/1947601911423031.
Results Reference
background
PubMed Identifier
30030240
Citation
Karaman S, Leppanen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease. Development. 2018 Jul 20;145(14):dev151019. doi: 10.1242/dev.151019.
Results Reference
background
PubMed Identifier
25415268
Citation
Cardenas-Cantu E, Zavala J, Valenzuela J, Valdez-Garcia JE. Molecular Basis of Pterygium Development. Semin Ophthalmol. 2016;31(6):567-83. doi: 10.3109/08820538.2014.971822. Epub 2014 Nov 21.
Results Reference
background
PubMed Identifier
32545222
Citation
Rossino MG, Lulli M, Amato R, Cammalleri M, Monte MD, Casini G. Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy. Cells. 2020 Jun 11;9(6):1452. doi: 10.3390/cells9061452.
Results Reference
background

Learn more about this trial

Effects of Ranibizumab in Primary Pterygium Surgery

We'll reach out to this number within 24 hrs